Published in J Clin Oncol on May 01, 2005
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer (2014) 0.81
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment. Breast Cancer Res (2009) 0.78
Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. Br J Cancer (2015) 0.78
High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer (2008) 0.77
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer. PLoS One (2014) 0.77
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clin Cancer Res (2016) 0.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol (2006) 4.87
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol (2012) 2.36
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol (2011) 2.14
Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin Breast Cancer (2010) 2.12
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer (2011) 1.79
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg (2003) 1.71
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol (2009) 1.68
Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery (2008) 1.57
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol (2006) 1.56
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol (2011) 1.52
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Dual-energy contrast-enhanced digital mammography: initial clinical results. Eur Radiol (2010) 1.28
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
Contrast-enhanced digital mammography. Eur J Radiol (2008) 1.17
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res (2012) 1.16
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat (2010) 1.13
Laser thermal therapy: real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. Lasers Surg Med (2011) 1.13
New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. Eur J Radiol (2008) 1.12
Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol (2010) 1.12
Splenic parenchymal complications in pancreatitis. JOP (2011) 1.08
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs (2011) 1.07
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res (2007) 1.05
CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist (2009) 1.05
Surgical clips assist in the visualization of the lumpectomy cavity in three-dimensional conformal accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys (2010) 1.05
Cost-effectiveness of a genetic test for breast cancer risk--letter. Cancer Prev Res (Phila) (2014) 1.05
CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet (2013) 1.05
Granular cell tumor of the breast. Diagn Cytopathol (2007) 1.02
Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol (2012) 1.01
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res (2013) 0.98
Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol (2010) 0.98
Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer (2005) 0.98
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol (2011) 0.96
Outcome of full-thickness chest wall resection for isolated breast cancer recurrence. Eur J Cardiothorac Surg (2013) 0.96
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95
Dynamic optical breast imaging: a new technique to visualise breast vessels: comparison with breast MRI and preliminary results. Eur J Radiol (2005) 0.95
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95
Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer (2002) 0.95
Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer (2004) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Changes in psychological adjustment over the course of treatment for breast cancer: the predictive role of social sharing and social support. Psychooncology (2013) 0.94
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother (2012) 0.94
3D-conformal accelerated partial breast irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity. Radiat Oncol (2009) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer (2012) 0.93
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer (2011) 0.92
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol (2008) 0.91
Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues. Inorg Chem (2011) 0.91
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol (2013) 0.90
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat (2013) 0.90
Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Res (2014) 0.89
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol (2008) 0.89
Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol (2013) 0.88
Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86
Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am J Surg (2013) 0.86
Epidermal panfolliculoma: an adnexal proliferation with advanced follicular differentiation confined to the epidermis. J Cutan Pathol (2013) 0.85
Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial). Int J Radiat Oncol Biol Phys (2010) 0.85
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85